1. GLOBOCAN 2012: Estimated Incidence, Mortality and Prevalence Worldwide in 2012. All Cancers (excluding non-melanoma skin cancer) (base de datos en internet). Disponible en: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx. Acceso: enero 2016.
2. GLOBOCAN 2012: Estimated Incidence, Mortality and Prevalence Worldwide in 2012. Lung Cancer (base de datos en internet). Disponible en: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx. Acceso: enero 2016.
3. Anuario Estadístico de Salud 2014. Dirección Nacional de Registros Médicos y Estadísticas de Salud. Ministerio de Salud Pública. Cuba. La Habana 2015.
4. Argiris A, Murren JR. Staging and clinical prognostic factors for small-cell lung cancer. Cancer J. 2001 Sep-Oct;7(5):437-47.
5. Spiegelman D, Maurer LH, Ware JH, Perry MC, Chahinian AP, Comis R, et al. Prognostic factors in small-cell carcinoma of the lung: an analysis of 1,521 patients. J Clin Oncol. 1989 Mar;7(3):344-54.
6. Wolf M, Holle R, Hans K, Drings P, Havemann K. Analysis of prognostic factors in 766 patients with small cell lung cancer (SCLC): the role of sex as a predictor for survival. Br J Cancer. 1991 Jun;63(6):986-92.
7. Chiappori AA, Soliman H, Janssen WE, Antonia SJ, Gabrilovich DI. INGN-225: a dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effect. Expert Opin Biol Ther. 2010 Jun;10(6):983-91.
8. Sekine I, Nishiwaki Y, Kakinuma R, Kubota K, Hojo F, Matsumoto T, et al. Phase I/II trial of weekly cisplatin, etoposide, and irinotecan chemotherapy for metastatic lung cancer: JCOG 9507. Br J Cancer. 2003 Mar 24;88(6):808-13.
9. Sunpaweravong P, Magree L, Rabinovitch R, Bunn P, Kelly K, Eguchi K, et al. A phase I/II study of docetaxel, etoposide, and carboplatin before concurrent chemoradiotherapy with cisplatin and etoposide in limited-stage small cell lung cancer. Invest New Drugs. 2006 May;24(3):213-21.
10. Hanna N, Bunn PA Jr, Langer C, Einhorn L, Guthrie T Jr, Beck T, et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol. 2006 May 1;24(13):2038-43.
11. National Comprehensive Cancer Network Version1.2016. Small Cell Lung Cancer.
12. Reck M, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. Ann Oncol. 2013 Jan;24(1):75-83.
13. Mavroudis D, Papadakis E, Veslemes M, Tsiafaki X, Stavrakakis J, Kouroussis C, et al. A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as first-line treatment in patients with small-cell lung cancer. Ann Oncol. 2001 Apr;12(4):463-70.
14. West L, Vidwans SJ, Campbell NP, Shrager J, Simon GR, Bueno R, et al. A novel classification of lung cancer into molecular subtypes. PLoS One. 2012;7(2):e31906.
15. Spigel DR, Socinski MA. Rationale for chemotherapy, immunotherapy, and checkpoint blockade in SCLC: beyond traditional treatment approaches. J Thorac Onccol. 2013 May;8(5):587-98.
16. Saunders LR, Bankovich AJ, Anderson WC, Aujay MA, Bheddah S, Black K, et al. A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo. Sci Transl Med. 2015 Aug 26;7(302):302ra136.
17. Villaruz LC, Kalyan A, Zarour H, Socinski MA. Immunotherapy in lung cancer. Transl Lung Cancer Res. 2014 Feb;3(1):2-14.
18. Massarelli E, Papadimitrakopoulou V, Welsh J, Tang C, Tsao AS. Immunotherapy in lung cancer. Transl Lung Cancer Res. 2014 Feb;3(1):53-63.
19. Miyake M, Hashimoto K, Ito M, Ogawa O, Arai E, Hitomi S, et al.The abnormal occurrence and the differentiation-dependent distribution of N-acetyl and N-glycolyl species of the ganglioside GM2 in human germ cell tumors. Cancer. 1990;65(3):499-505.
20. Durrant LG, Noble P, Spendlove I. Immunology in the clinic review series; focus on cancer: glycolipids as targets for tumour immunotherapy. Clin Exp Immunol. 2012;167(2):206-15.
21. Wiegandt H. The chemical structures of gangliosides. En: Oettgen HF, Ed. Gangliosides and cancer, VCH Publishers, New York, 1989.
22. Herberman RB. Tumor immunology. JAMA. 1992;268:2935-2939.
23. Tsuchida T, Saxton RE, Morton DL, Irie RF. Gangliosides of human melanoma. J Natl Cancer Inst 78:45, 1987.
24. Cazet A, Julien S, Bobowski M, Burchell J, Delannoy P. Tumour-associated carbohydrate antigens in breast cancer. Breast Cancer Res. 2010;12(3):204.
25. Marquina G, Waki H, Fernandez LE, Kon K, Carr A, Valiente O, et al. Gangliosides expressed in human breast cancer. Cancer Res. 1996;56(22):5165-71.
26. Estevez F, Carr A, Solorzano L, Valiente O, Mesa C, Barroso O, et al. Enhancement of the immune response to poorly immunogenic gangliosides after incorporation into very small size proteoliposomes (VSSP). Vaccine. 1999;18(1-2):190-7.
27. Carr A, Mullet A, Mazorra Z, Vázquez AM, Alfonso M, Mesa C, et al. A Mouse IgG1 Monoclonal Antibody Specific for N-GlycolylGM3 Ganglioside Recognized Breast and Melanoma Tumors. HYBRIDOMA. 2000;19(3):241-247.
28. Blanco R, Quintana Y, Blanco D, Cedeño M, Rengifo CE, Frómeta M, et al. Tissue reactivity of the 14F7 Mab raised against NGlycolylGM3 ganglioside in tumors of neuroectodermal, mesodermal and epithelial origin. Journal of Biomarkers. 2013
29. Blanco R, Blanco D, Quintana Y, Escobar X, Rengifo CE, Osorio M, et al. Immunoreactivity of the 14F7 Mab raised against NGlycolylGM3 ganglioside in primary lymphoid tumors and lymph node metastasis. Patholog Res Int. 2013;2013:920972. Epub 2013 Nov 28),
30. Bada A, Casaco A, Arteaga M, Martinez J, Leon A, Santana E, et al. Toxicity of a GM3 cancer vaccine in Macaca fascicularis monkey: a 12-month Study. Hum Exp Toxicol. 2002;21(5):263-7.
31. Labrada M, Clavell M, Bebelagua Y, León J, Alonso DF, Gabri MR, et al. Direct validation of NGcGM3 ganglioside as a new target for cancer immunotherapy. Expert Opin Biol Ther. 2010;10(2):153-62.
32. Labrada M. Induction of leukocyte infiltration at metastatic site mediates the protective effect of NGcGM3-based vaccine. Human Vaccines and Immunotherapeutics. En prensa 2014.
33. Carr A, Rodríguez E, Arango MC, Camacho R, Osorio M, Gabri M, et al. Immunotherapy of advanced breast cancer with a heterophilic ganglioside (NeuGcGM3) cancer vaccine. J Clin Oncol. 2003;21(6):1015-21.
34. Registro Clínico. Inmunoterapia activa específica con la vacuna NGcGM3/VSSP/Montanide ISA 51 en pacientes con cáncer de mama metastásico. Fase II. Disponible en: http://registroclinico.sld.cu/en/trials/RPCEC00000068-En
35. De la Torre A, Hernández J, Ortiz R, Cepeda M, Pérez K, Car A, et al. NGlycolylGM3/VSSP vaccine in metastatic breast cancer patients: results of Phase I/IIa clinical trial. Breast Cancer (Auckl). 2012;6:151-7.
36. Osorio M, Gracia E, Reigosa E, Hernández J, de la Torre A, Saurez G, et al. Effect of vaccination with N-glycolyl GM3/VSSP vaccine by subcutaneous injection in patients with advanced cutaneous melanoma. Cancer Manaq Res. 2012;4:341-5.
37. De la Torre A, Pérez K, Vega AM, Santiesteban E, Ruiz R, Hernández L, et al. Superior Efficacy and Safety of a Nonemulsive Variant of the NGcGM3/VSSP Vaccine in Advanced Breast Cancer Patients. Breast Cancer : Basic and Clinical Research. 2016;10:5-11.
38. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228-47.